Trial Profile
Fosaprepitant versus Ondansetron for prevention of postoperative nausea and vomiting in oral and maxillofacial surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Ondansetron
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 25 Mar 2016 Status changed from recruiting to completed.
- 15 Dec 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
- 14 Oct 2015 New trial record